MBC PHARMA, INC.
Biotech · Private
Bone-targeted antibiotic conjugates combining approved antibiotics (ciprofloxacin, clindamycin) with bisphosphonates via biodegradable linkers for osteomyelitis treatment
- Grants
- $3.0M
- 6 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 12
- 4 granted · 8 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20152016201720182019
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Novel Bone-Targeting Combination Therapy for Osteosarcoma | $301,877 | |
| Federal grant | Department of Health and Human Services · Phase I · Bone Targeted Antibiotics | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel Bone-Targeting Combination Therapy for Osteosarcoma Phase II | $1,138,475 | |
| Federal grant | Department of Health and Human Services · Phase I · Bone Targeted Antibiotics | $294,202 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel Bone-Targeting Combination Therapy for Osteosarcoma Phase II | $860,229 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel Bone-Targeting Combination Therapy for Osteosarcoma Phase II | $136,623 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 3248 | SYMBIOTICA, INC. | — | — |
| 3249 | SCI-ENGI-MEDCO SOLUTIONS, INC | — | — |
| 3250 | Haplomics | — | — |
| 3251 | MBC PHARMA, INC. | — | — |
| 3252 | OM BHARTI LLC | — | — |
| 3253 | Percept Corp | — | $4.8M |
| 3254 | Cellarcus Biosciences, Inc. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Drug Combination Treatments Using Bone-targeting Therapeutics For Bone And Bone-related Diseasegranted
- Ibandronate Conjugates Of Nucleoside Antimetabolitesgranted
- Bone Targeted Therapeutics And Methods Of Making And Using The Sameapplication
- Bone Targeted Therapeutics and Methods of Making and Using the Samegranted
- Vitamin B6 Derivatives Of Nucleotides, Acyclonucleotides And Acyclonucleoside Phosphonatesapplication
- Bone Targeted Therapeutics and Methods of Making and Using the Samegranted
- Vitamin B6 Derivatives Of Nucleotides, Acyclonucleotides And Acyclonucleoside Phosphonatesapplication
- Vitamin B6 Derivatives Of Nucleotides, Acyclonucleotides And Acyclonucleoside Phosphonatesapplication
- Drug Combination Treatments Using Bone-targeting Therapeutics For Bone And Bone-related Diseaseapplication
- Ibandronate Conjugates Of Nucleoside Antimetabolitesapplication
- Ibandronate Conjugates Of Nucleoside Antimetabolitesapplication
- Bone Targeted Drug Combinationapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.